News

Merck & Co. Inc. stock outperforms competitors on strong trading day
Merck & Co. Inc. closed 39.23% short of its 52-week high of $134.63, which the company reached on June 25th.
Fierce Biotech11d
Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech: FT
Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...
Fierce Pharma5d
Feeling RSV heat from Merck, Sanofi lays out early supply plans for Beyfortus
One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...
Merck Wins US Approval for Shot to Prevent Infant RSV
Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...
Fierce Biotech5d
Merck's leader in oral PCSK9 inhibitor race reduces cholesterol in pair of phase 3 trials
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
Merck & Co. Inc. stock underperforms Wednesday when compared to competitors
The stock's fall snapped a three-day winning streak.
Explore more
Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials
Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda
Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...
BioPharma Dive5d
Merck claims study success with PCSK9 cholesterol pill
Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...
News-Medical.Net on MSN19h
Benchling and Merck collaborate on vaccine bioanalysis
Benchling announced a new collaboration with Merck, known as MSD outside of the United States and Canada, to implement a ...
InvestorsHub on MSN2d
Merck Launches Final-Stage Trial of Dengue Vaccine for Children
Merck & Co Inc (NYSE:MRK) has begun a Phase 3 clinical trial to test its experimental dengue vaccine in a pediatric ...